Effect of LY2165766 on Body Weight in Healthy Subjects

Effect of LY2165766 on Body Weight in Healthy Subjects - LY2165766 effect on body weight in healthy subjects

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON33288

Enrollment

105

Registered

2009-07-20

Start date

2009-08-28

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Study Medication Active substance :LY2165766 olanzapine Activity : unknown antipsychotic Indication : unknown schizophrenia Strength : 10 mg 10 mg Dosage form :capsule tablet An oral dose of 10 mg L

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy male 18 - 55 years of age Healthy female 45 - 55 years of age, postmenopausal/sterilised BMI 18.5 - 30 inclusive

Exclusion criteria

Exclusion criteria: relevant medical history

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)